Pharmacotherapeutic management of pseudobulbar affect

Am J Manag Care. 2017 Dec;23(18 Suppl):S345-S350.

Abstract

This activity will update pharmacists and other healthcare professionals on current treatments for pseudobulbar affect (PBA). Points of discussion will focus on the off-label therapies traditionally used to treat PBA, the FDA-approved combination drug product with PBA as an indication, and managed care aspects of treating PBA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Drug Approval
  • Drug Therapy / methods*
  • Drugs, Investigational / therapeutic use*
  • Female
  • Humans
  • Male
  • Medication Therapy Management
  • Patient Safety*
  • Pseudobulbar Palsy / diagnosis
  • Pseudobulbar Palsy / drug therapy*
  • Risk Assessment
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antidepressive Agents, Tricyclic
  • Drugs, Investigational
  • Serotonin Uptake Inhibitors